NCT02974738View on ClinicalTrials.gov

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

January 12, 2018

Study Completion Date

April 14, 2027

Conditions
Advanced Solid TumorsSolid TumorSolid CarcinomaSolid Tumor, AdultccRCCRCC, Clear Cell AdenocarcinomaRCCKidney CancerClear Cell Renal Cell CarcinomaRenal Cell Carcinoma, MetastaticRenal Cell Carcinoma RecurrentRenal Cell Carcinoma, Clear Cell AdenocarcinomaGlioblastomaGlioblastoma, AdultGBMGlioblastoma Multiforme
Interventions
DRUG

Belzutifan

Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis

All Listed Sponsors
lead

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY